Akero(AKRO) - 2024 Q3 - Quarterly Results

Exhibit 99.1 akEro Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update — First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH — Phase 3 SYNCHRONY Real-World and Histology studies on track to report results for their respective primary endpoints in 2026 and the first half of 2027 — — Phase 2b SYMMETRY study week 96 results expected to readout in February 2025 — SOUTH SAN F ...